Formosa Pharmaceuticals, Inc. (TPE:6838)

Market Cap	3.76B +1.6%
Revenue (ttm)	54.32M +236.4%
Net Income	-58.08M
EPS	-0.38
Shares Out	150.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	122,377
Open	24.75
Previous Close	24.75
Day's Range	24.75 - 25.00
52-Week Range	24.75 - 43.45
Beta	0.73
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Formosa Pharmaceuticals

Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and color...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6838

Financial Performance

In 2025, Formosa Pharmaceuticals's revenue was 9.50 million, a decrease of -93.38% compared to the previous year's 143.36 million. Losses were -83.57 million, -58.43% less than in 2024.